RT Journal Article
SR Electronic
T1 Addressing Personal Protective Equipment (PPE) Decontamination: Methylene Blue and Light Inactivates SARS-CoV-2 on N95 Respirators and Masks with Maintenance of Integrity and Fit
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.11.20236919
DO 10.1101/2020.12.11.20236919
A1 Thomas S. Lendvay
A1 James Chen
A1 Brian H. Harcourt
A1 Florine E.M. Scholte
A1 F. Selcen Kilinc-Balci
A1 Ying Ling Lin
A1 Molly M. Lamb
A1 Larry F. Chu
A1 Amy Price
A1 David Evans
A1 Yi-Chan Lin
A1 Christopher N. Mores
A1 Jaya Sahni
A1 Kareem B. Kabra
A1 Eric Haubruge
A1 Etienne Thiry
A1 Belinda Heyne
A1 Jan Laperre
A1 Sarah Simmons
A1 Jan M. Davies
A1 Yi Cui
A1 Thor Wagner
A1 Tanner Clark
A1 Sarah J. Smit
A1 Rod Parker
A1 Thomas Gallagher
A1 Emily Timm
A1 Louisa F. Ludwig-Begall
A1 Nicolas Macia
A1 Cyrus Mackie
A1 Karen Hope
A1 Ken Page
A1 Susan Reader
A1 Peter Faris
A1 Olivier Jolois
A1 Alpa Patel
A1 Jean-Luc Lemyre
A1 Vanessa Molloy-Simard
A1 Kamonthip Homdayjanakul
A1 Sarah R. Tritsch
A1 Constance Wielick
A1 Mark Mayo
A1 Rebecca Malott
A1 Jean-Francois Willaert
A1 Hans Nauwynck
A1 Lorène Dams
A1 Simon De Jaeger
A1 Lei Liao
A1 Mervin Zhao
A1 Steven Chu
A1 John M. Conly
A1 May C. Chu
YR 2020
UL http://medrxiv.org/content/early/2020/12/12/2020.12.11.20236919.abstract
AB Background The coronavirus disease 2019 (COVID-19) pandemic has resulted in severe shortages of personal protective equipment (PPE) necessary to protect front-line healthcare personnel. These shortages underscore the urgent need for simple, efficient, and inexpensive methods to decontaminate SARS-CoV-2-exposed PPE enabling safe reuse of masks and respirators. Efficient decontamination must be available not only in low-resourced settings, but also in well-resourced settings affected by PPE shortages. Methylene blue (MB) photochemical treatment, hitherto with many clinical applications including those used to inactivate virus in plasma, presents a novel approach for widely applicable PPE decontamination. Dry heat (DH) treatment is another potential low-cost decontamination method.Methods MB and light (MBL) and DH treatments were used to inactivate coronavirus on respirator and mask material. We tested three N95 filtering facepiece respirators (FFRs), two medical masks (MMs), and one cloth community mask (CM). FFR/MM/CM materials were inoculated with SARS-CoV-2 (a Betacoronavirus), murine hepatitis virus (MHV) (a Betacoronavirus), or porcine respiratory coronavirus (PRCV) (an Alphacoronavirus), and treated with 10 µM MB followed by 50,000 lux of broad-spectrum light or 12,500 lux of red light for 30 minutes, or with 75°C DH for 60 minutes. In parallel, we tested respirator and mask integrity using several standard methods and compared to the FDA-authorized vaporized hydrogen peroxide plus ozone (VHP+O3) decontamination method. Intact FFRs/MMs/CM were subjected to five cycles of decontamination (5CD) to assess integrity using International Standardization Organization (ISO), American Society for Testing and Materials (ASTM) International, National Institute for Occupational Safety and Health (NIOSH), and Occupational Safety and Health Administration (OSHA) test methods.Findings Overall, MBL robustly and consistently inactivated all three coronaviruses with at least a 4-log reduction. DH yielded similar results, with the exception of MHV, which was only reduced by 2-log after treatment. FFR/MM integrity was maintained for 5 cycles of MBL or DH treatment, whereas one FFR failed after 5 cycles of VHP+O3. Baseline performance for the CM was variable, but reduction of integrity was minimal.Interpretation Methylene blue with light and DH treatment decontaminated masks and respirators by inactivating three tested coronaviruses without compromising integrity through 5CD. MBL decontamination of masks is effective, low-cost and does not require specialized equipment, making it applicable in all-resource settings. These attractive features support the utilization and continued development of this novel PPE decontamination method.Competing Interest StatementAuthors Thomas S. Lendvay, James Chen are Co-Founders and equity owners of Singletto, Inc. (Seattle, WA, USA) Authors Yi Cui and Steven Chu are Co-Founders and equity owners of 4C Air, Inc. (Sunnyvale, CA)Funding StatementThis study was funded by Open Philanthropy; Amazon Inc./University of Washington Catalyst Award; University of Liege (Belgium) and the Walloon Region, Belgium; Li Ka Shing Institute; Alberta Health Services; and an Anonymous donor to the University of Washington, Department of Urology.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Stanford University and Alberta Health Services/University of Calgary were exempt from IRB as the human fit testing was considered Quality Improvement. ERB for clinical specimen use: A clinical saliva specimen with a SARS-CoV-2 was provided by Dr. John Conly from Calgary, Alberta with Calgary ERB approval (ID# Pro00099761).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be freely shared post publication on reasonable request by contacting the corresponding author of the study.